These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 35998145)
41. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
42. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity. Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779 [TBL] [Abstract][Full Text] [Related]
43. Synthesis of 1H-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Agents. Awolade P; Cele N; Ebenezer O; Kerru N; Gummidi L; Gu L; Palma G; Kaur M; Singh P Anticancer Agents Med Chem; 2021; 21(10):1228-1239. PubMed ID: 32990543 [TBL] [Abstract][Full Text] [Related]
44. Anti-cancer stem cell activity of a sesquiterpene lactone isolated from Ambrosia arborescens and of a synthetic derivative. Sotillo WS; Villagomez R; Smiljanic S; Huang X; Malakpour A; Kempengren S; Rodrigo G; Almanza G; Sterner O; Oredsson S PLoS One; 2017; 12(9):e0184304. PubMed ID: 28863191 [TBL] [Abstract][Full Text] [Related]
45. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors. El-Adl K; El-Helby AA; Sakr H; Elwan A Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414 [TBL] [Abstract][Full Text] [Related]
46. Single crystal XRD, DFT investigations and molecular docking study of 2- ((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)naphthalene-1,4-dione as a potential anti- cancer lead molecule. P R KR; Mary YS; Fernandez A; S AP; Mary YS; Thomas R Comput Biol Chem; 2019 Feb; 78():153-164. PubMed ID: 30530296 [TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents. Luo Y; Wu W; Zha D; Zhou W; Wang C; Huang J; Chen S; Yu L; Li Y; Huang Q; Zhang J; Zhang C Bioorg Med Chem Lett; 2021 Sep; 47():128230. PubMed ID: 34186178 [TBL] [Abstract][Full Text] [Related]
48. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782 [TBL] [Abstract][Full Text] [Related]
49. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
50. Dehydrocostus Lactone Suppresses Proliferation of Human Chronic Myeloid Leukemia Cells Through Bcr/Abl-JAK/STAT Signaling Pathways. Cai H; Qin X; Yang C J Cell Biochem; 2017 Oct; 118(10):3381-3390. PubMed ID: 28300289 [TBL] [Abstract][Full Text] [Related]
51. Synthesis of 6-epi-tuberiferin and the biological activities of tuberiferin, dehydrobrabrachylaenolide, 6-epi-tuberiferin, and their synthetic intermediates. Li D; Higuchi Y; Kobayashi T; Shimoma F; Bai Y; Ando M Bioorg Chem; 2021 Mar; 108():104642. PubMed ID: 33517005 [TBL] [Abstract][Full Text] [Related]
52. Design, Synthesis, Structure-Activity Relationship and Docking Studies of Novel Functionalized Arylvinyl-1,2,4-Trioxanes as Potent Antiplasmodial as well as Anticancer Agents. Tiwari MK; Coghi P; Agrawal P; Shyamlal BRK; Jun Yang L; Yadav L; Peng Y; Sharma R; Yadav DK; Sahal D; Kam Wai Wong V; Chaudhary S ChemMedChem; 2020 Jul; 15(13):1216-1228. PubMed ID: 32392362 [TBL] [Abstract][Full Text] [Related]
53. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting. El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460 [TBL] [Abstract][Full Text] [Related]
54. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors. Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307 [TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and biological activity evaluation of novel scopoletin-NO donor derivatives against MCF-7 human breast cancer in vitro and in vivo. Yu N; Li N; Wang K; Deng Q; Lei Z; Sun J; Chen L Eur J Med Chem; 2021 Nov; 224():113701. PubMed ID: 34315044 [TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712 [TBL] [Abstract][Full Text] [Related]
60. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells. Nafie MS; Amer AM; Mohamed AK; Tantawy ES Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]